BioVex Company Profile
BioVex is a three year old private biotech company that is developing a new class of potent vaccines principally to treat and prevent cancer. The Company is headquartered in Oxford, UK.
The Company has three technology platforms based on the manipulation of the herpes simplex type one virus. The Company has two vaccine platforms; OncoVEX and ImmunoVEX and a functional genomics platform for gene determination in the nervous system (NeuroVEX)
The Company’s lead product OncoVEX GM-CSF is to enter Phase I/II studies in early 2002 in breast cancer, head and neck cancer and malignant melanoma. OncoVEX GM-CSF is scheduled to be the first lytic HSV vector (that selectively destroys tumour cells) containing an immune stimulating molecule to move into clinical development. It has the potential to treat metastatic as well as local disease.
The Company’s ImmunoVEX vaccine platform stimulates a key class of immune policing (dendritic) cells. The Company’s lead product to treat malignant melanoma is expected to enter the clinic in the first quarter of 2003.
The Company also has a portfolio of vaccines to treat other cancers and chronic infectious diseases for which pre-clinical data sets are being assembled. These include products for lung cancer, prostate cancer, HSV/HPV and Hepatitis B.
Location
BioVex Ltd, 70 Milton Park, Abingdon
Oxon
Oxfordshire
OX14 4RX
United Kingdom
Contact
Phone: +44 (0)1235 441900
Fax: +44 (0)1235 441901
Email: gbeynon@biovex.com
News Articles
uniQure Appoints Philip Astley-Sparke President US
AMSTERDAM, January 22, 2013 /PRNewswire/ -- uniQure B.V., the leader in the field of human gene therapy, today announced the appointment of Philip Astley-Sparke, former President and CEO of BioVex, a...
Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner
Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO of BioVex, has joined the investment team as a venture partner based in Boston, USA. He...
Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle
The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.
Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner.
Naarden, The Netherlands, Munich, Germany and Boston, USA, 10 September 2012 - Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO of BioVex, has joined th...
Good News in Oncology: Oncolytic Virus Therapy
The last few days have brought some good news on some unusual approaches to cancer therapy. First off was Amgen's report that they'd seen positive results in advanced melanoma using a modified HSV tre...
Amgen M&A deals and alliances 2005-2013
Amgen has announced over 11 M&A deals since 2005, with the lead deals being the acquisition of decode Genetics, MN Pharmaceuticals, KAI Pharmaceuticals, Micromet and Biovex. Abstracted from: Partn...
Forbion announces Amgen agreement to acquire portfolio company Biovex for up to US$1 billion.
Acquisition of a Potential, First-in-Class Cancer Therapeutic in Late-Stage Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer Naarden, The Netherlands, 24 January...
Summary Website: Amgen Headquarters: Thousand Oaks CA, USA Ticker Symbol: AMGN (Nasdaq Stock Exchange) AMG (Frankfurt Stock Exchange) SEC Link: Amgen Subsidiaries: Abgenix Alantos Pharmaceuticals...
Drugs and Medications
None
PubMed Articles
The innovative evolution of cancer gene and cellular therapies.
We provide an overview of the latest developments in cancer gene therapy-from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scient...
Clinical Trials
None
Companies
BioVex is a privately held biotechnology company based in Woburn, Mass. where it also has an operational launch grade manufacturing facility. The Company is developing a new class...
BioVex is a privately held biotechnology company based in Woburn, Mass. where it also has an operational launch grade manufacturing facility. The Company is developing a new class...
BioVex is a three year old private biotech company that is developing a new class of potent vaccines principally to treat and prevent cancer. The Company is headquartered in Oxford, UK. The Company ha...
More Information about "BioVex" on BioPortfolio
We have published hundreds of BioVex news stories on BioPortfolio along with dozens of BioVex Clinical Trials and PubMed Articles about BioVex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioVex Companies in our database. You can also find out about relevant BioVex Drugs and Medications on this site too.
